Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Given Consensus Rating of “Moderate Buy” by Analysts

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $17.1111.

A number of equities analysts have commented on ADPT shares. Guggenheim initiated coverage on shares of Adaptive Biotechnologies in a research note on Tuesday, September 30th. They issued a “buy” rating and a $20.00 price objective for the company. Wall Street Zen upgraded Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 7th. Piper Sandler raised their price objective on Adaptive Biotechnologies from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, October 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, October 8th.

Adaptive Biotechnologies Price Performance

NASDAQ:ADPT opened at $17.52 on Friday. The company has a market cap of $2.67 billion, a price-to-earnings ratio of -32.44 and a beta of 2.18. Adaptive Biotechnologies has a 1 year low of $6.26 and a 1 year high of $20.76. The stock’s 50 day simple moving average is $16.60 and its two-hundred day simple moving average is $14.50.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Wednesday, November 5th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. Adaptive Biotechnologies had a negative net margin of 31.50% and a negative return on equity of 58.40%. The firm had revenue of $93.97 million during the quarter, compared to analyst estimates of $58.76 million. During the same period last year, the firm posted ($0.22) earnings per share. Adaptive Biotechnologies’s revenue for the quarter was up 102.4% compared to the same quarter last year. As a group, analysts anticipate that Adaptive Biotechnologies will post -0.92 EPS for the current year.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Francis Lo sold 113,890 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $15.57, for a total transaction of $1,773,267.30. Following the transaction, the insider owned 315,978 shares in the company, valued at $4,919,777.46. The trade was a 26.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Kyle Piskel sold 162,820 shares of the stock in a transaction on Friday, November 28th. The shares were sold at an average price of $19.50, for a total transaction of $3,174,990.00. Following the completion of the sale, the chief financial officer directly owned 216,637 shares in the company, valued at approximately $4,224,421.50. This represents a 42.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 1,442,530 shares of company stock valued at $24,610,748 over the last three months. Corporate insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Brighton Jones LLC increased its stake in Adaptive Biotechnologies by 3.1% in the 3rd quarter. Brighton Jones LLC now owns 23,301 shares of the company’s stock worth $349,000 after buying an additional 700 shares during the period. Bouvel Investment Partners LLC grew its stake in Adaptive Biotechnologies by 2.2% in the 3rd quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company’s stock worth $641,000 after acquiring an additional 904 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Adaptive Biotechnologies by 3.1% during the second quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company’s stock worth $355,000 after acquiring an additional 910 shares during the period. California State Teachers Retirement System raised its stake in shares of Adaptive Biotechnologies by 1.0% during the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock valued at $1,145,000 after acquiring an additional 933 shares in the last quarter. Finally, Captrust Financial Advisors raised its stake in shares of Adaptive Biotechnologies by 7.6% during the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after acquiring an additional 1,119 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.